Tianxin Pharmaceutical's VA, VB5, cholesterol and calcifediol project 07-02-2021

Summary: On 7 June, the Jingdezhen Ecology and Environment Bureau of Jiangxi Province announced that the environmental impact assessment of Tianxin Pharmaceutical's VA, VB5, cholesterol and 25-hydroxyvitamin D3 project was approved. The products are all new for Tianxin Pharmaceutical.

On 7 June, the Jingdezhen Ecology and Environment Bureau of Jiangxi Province announced that the environmental impact assessment of Jiangxi Tianxin Pharmaceutical Co., Ltd. (Tianxin Pharmaceutical)'s VA, VB5, cholesterol and 25-hydroxyvitamin D3 project was approved. Previously, its sub-projects were published on the Leping People's Government of Jiangxi Province on 10 Aug., 2020. These projects include 1,000 t/a VA project, 7,000 t/a VB5 project and 6 t/a 25-hydroxyvitamin D3 project (Further details can be found in Vitamins China E-News 202008: Tianxin Pharmaceutical publicizes EIA reports of three new projects). As for the three sub-projects approved this time, there are some changes.

 

Tianxin Pharmaceutical's VA, VB5, cholesterol and 25-hydroxyvitamin D3 project

  • Total investment: USD213.73 million (RMB1,358,726,600)
  • Type: Restruction and expansion
  • Location: In the current and new lands of Tianxin Pharmaceutical's factory
  • Contents: The project (including 3 sub-projects), is divided into two phases. Facilities for VA, VB5, cholesterol and 25-hydroxyvitamin D3 production as well as complementary facilities (regenerated heavy distillate, regenerated activated carbon, hazardous waste incineration and industrial salt incineration) will be built up.
  • Capacity: 1,000 t/a retinyl acetate (converted to purification), 7,000 t/a VB5 (calcium pantothenate and pantothenic acid), 350 t/a cholesterol, 6 t/a 25-hydroxyvitamin D3 (converted to purification). All for external sales.
  • Complementary facilities: Regenerated heavy distillate (Phase I: 13.5 t/a; Phase II: 27 t/a), regenerated activated carbon (Phase II: 10,000 t/a), hazardous waste incineration (Phase I expansion: 30,000 t/a), industrial salt incineration (Phase II: additional 30,000 t/a).
  •  

    The three sub-projects are:

    1,000 t/a VA project

  • Total investment: USD122.90 million (RMB781,291,500)
  • Location: In the west of the new land for "Tianxin 2nd Area" in Tianxin Pharmaceutical's current factory
  • Contents: To build up new production facilities for VA
  •  

    7,000 t/a VB5 project

  • Total investment: USD72.36 million (RMB460,021,300)
  • Location: In the current land of "Tianxin 1st Area" in Tianxin Pharmaceutical's factory
  • Contents: To build up new production facilities for VB5
  •  

    350 t/a Cholesterol and 6 t/a 25-hydroxyvitamin D3 project

  • Total investment: USD18.47 million (RMB117,413,800)
  • Location: In the current land of "Tianxin 2nd Area" in Tianxin Pharmaceutical's factory
  • Contents: To build up new production facilities for cholesterol and 25-hydroxyvitamin D3
Table Capacity scheme of Tianxin Pharmaceutical's VA, VB5, cholesterol and 25-hydroxyvitamin D3 project
Production line Product Capacity (t/a) Quality indicators
Phase I Phase II Total
VA production line Retinyl acetate 333 667 1,000 GB14750-2010
VB5 production line VB5 (calcium pantothenate) 2,000 3,000 5,000 T/ZZB 1310-2019
VB5 (panthenol) / 2,000 2,000 GB/T33306-2016
Cholesterol and 25-hydroxyvitamin D3 production line Cholesterol 350 / 350 Pharmacopoeia of the People's Republic of China (Version 2020)
25-Hydroxyvitamin D3 6 / 6 USP2021


Source: Jiangxi Tianxin Pharmaceutical Co., Ltd.

Tianxin Pharmaceutical, the largest VB production base in China, is a high-tech company specializing in vitamin production. Currently, the company has products of 6,500 t/a VB6, 4,000 t/a VB1, 90 t/a VH, 500 t/a folic acid, 300 t/a L-ascorbyl palmitate, 45 t/a VD3, 10,000 t/a VB1 intermediate (liquid sodium methoxide), 20,000 t/a VB1 intermediate (acetamidine hydrochloride), 4,000 t/a VB6 intermediate (MEO), 180 t/a VH intermediate (thioester), 2,600 t/a folic acid intermediate (trichlor, triamine p-toluidine) and 45 t/a VD3 (intermediate).

 

The VA, VB5, cholesterol and 25-hydroxyvitamin D3 are all new production of Tianxin Pharmaceutical. According to the company, the project is built to meet market demand and to perfect its product mix. Advanced technology and equipment are adopted in the production of the project, and the indicators of resource consumption and pollutant generation are low. After the implementation of relevant environmental protection measures, all kinds of pollutants can be discharged up to the standard, with little pollution to the environment. Therefore, the project is feasible in the perspective of environmental protection.

 

At present, Tianxin Pharmaceutical is actively involved in VD3 and its derivatives. In April this year, the company passed the environmental protection for its 45 t/a VD3 production facility, which is now in normal production. If the cholesterol and 25-hydroxyvitamin D3 project can be put into production smoothly, it will extend the company's VD3 production chain.

 

25-hydroxyvitamin D3, also known as calcifediol, is an active metabolite of VD3. Mainly applied in feed industry, 25-hydroxyvitamin D3 not only has the function of ordinary VD3, but also can promote bone development of poultry animals and improve the quality of eggshell, thus reducing the rate of eggshell damages.

 

There are only a few producers of the product due to its high requirement on equipment and processes. The producers include DSM, Zhejiang Garden Biochemical High-Tech Co., Ltd. (designed production: 100 t/a feed grade 25-hydroxyvitamin D3; actual product: 25-hydroxy-7-dehydrocholesterol) and Shandong Haineng Bioengineering Co., Ltd. (capacity: 60 t/a feed grade 25-hydroxyvitamin D3). Tianxin Pharmaceutical will be a new producer of 25-hydroxyvitamin D3 if the project goes well.

 

Additionally, Zhejiang Garden Biochemical High-Tech Co., Ltd. (Garden Biochemical) is going to launch production of the feed grade 25-hydroxyvitamin D3. Garden Biochemical is the largest producer of VD3 in the world. The company is bullish on the 25-hydroxyvitamin D3 market and decides to build the 1,200 t/a 25-hydroxyvitamin D3 powder project in the Jinhua Economic & Technological Development Zone to increase its feed grade 25-hydroxyvitamin D3 capacity. On 19 Jan., 2021, Garden Biochemical revealed that the project will go into production in Q3 this year.

Source:CCM


You can find out more information at CCM Vitamin China Newsletter.


Main content of CCM Vitamin China Newsletter June 2021

1     Editor's Note                           
2     Governmental Direction                           
  2-1       Gelatinized confections listed as a dietary supplement dosage form for filing                     
3     Market Dynamics                           
  3-1       RedBull trademark disputes in China                     
4     Company Developments                           
  4-1       EIA report of Richen Biological's VK2 project publicized                     
  4-2       Haoyuan Chemexpress proposes to float on SSE                     
  4-3       Link Science and Technology launches IPO on SSE                     
  4-4       Tianxin Pharmaceutical's VA, VB5, cholesterol and calcifediol project                     
  4-5       Shengjinyuan Chemical to build m-cresol, sodium sulfate and m-toluidine project                     
  4-6       Harbin Pharmaceutical to increase capital to GNC Shanghai                     
5     Import and Export Analysis                           
  5-1       Imports and exports of selected vitamins in China, April 2021                     
  5-2       April witnesses MoM decrease in China's vitamin exports                     
6     Price Update                           
  6-1       Ex-works prices of selected vitamins in China, June 2021                     
  6-2       Price of VK3 raw material rises in June                     
7     News in Brief                           
  7-1       Bohou Biotechnology's pure VA pilot production project                     
  7-2       Hengrui Pharmaceutical's paricalciitol injections pass GCE                     
  7-3       Biostime Inc. fined for substandard VA in goat milk powder formula                     
  7-4       283 Drug registration certificates to be deregistered                     
  7-5       Projects in Chengdu Pharmaceutical Zone kick-started                     
  7-6       Guangzhou Nansha under temporary lockdown                     
  7-7       Weisheng Pharmaceutical's VC technological upgrading project                     
  7-8       Zhongsheng Pharmaceutical reveals NMN production of its subsidiary                     
  7-9       Luwei Pharmaceutical Group launches new VC products                     
   7-10        Zhejiang NHU's VE factory suspended for maintenance

About CCM:

CCM is the leading market intelligence provider for China’s agriculture, chemicals, food & feed and life science markets. Founded in 2001, CCM offers a range of data and content solutions, from price and trade data to industry newsletters and customized market research reports. CCM is a brand of Kcomber Inc.

 

For more information about CCM, please visit www.cnchemicals.com or get in touch with us directly by emailing econtact@cnchemicals.com or calling +86-20-37616606.



Subscribe to our Newsletter

 


Next Press